The Oxford/AstraZeneca, what you need to know https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know The vaccine is safe and effective for all individuals aged 18 and above. https://www.bhf.org.uk/informationsupport/heart-matters-magazine/news/coronavirus-and-your-health/astrazeneca-covid-vaccine Is the AstraZeneca vaccine still being used in the UK? No, the UK government is not ordering future supplies of the AstraZeneca Covid-19 vaccine. Evidence shows that mRNA vaccines, Pfizer and Moderna, are more effective at boosting protection from Covid-19, so these vaccines are being recommended for the autumn booster programme. Yellow cards https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting COVID-19 Vaccine AstraZeneca https://yellowcard.mhra.gov.uk/idaps/CHADOX1%20NCOV-19 Essential context https://yellowcard.mhra.gov.uk/idaps/CHADOX1%20NCOV-19 The Medicines and Healthcare products Regulatory Agency (MHRA) Yellow card scheme, Don’t wait for someone else to report it https://www.gov.uk/drug-safety-update/yellow-card-please-help-to-reverse-the-decline-in-reporting-of-suspected-adverse-drug-reactions Only 10% of serious reactions reported Only 2 and 4% of non-serious reactions are reported via yellow cards. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsbyvaccinationstatusengland Deaths by vaccination status mRNA Vaccine, serious adverse events of special https://pubmed.ncbi.nlm.nih.gov/36055877/ 3.4. Harm-benefit considerations In the Moderna trial One in 662 In the Pfizer trial One in 990 Combined One in 800 (over placebo baselines) Latest risk figures from UK Health Security Agency (UKHSA) presentation to the Joint Committee on Vaccination and Immunisation (JCVI) https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1131409/appendix-1-of-jcvi-statement-on-2023-covid-19-vaccination-programme-8-november-2022.pdf Table 3: NNV for prevention of hospitalisation (and severe hospitalisation) for different programmes 20 – 29 Years, Autumn booster No risk group, 169,200 (706,500) In a risk group, 7,500 (59,500) 50 – 59 Years, Autumn booster No risk group, 43,600 (256,400) In a risk group, 3,100 (18,600) ONS, death data, W/E 27th January https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredweeklyinenglandandwalesprovisional/weekending27january2023 Deaths registered in the UK was 15,953 2.1% above the five-year average (321 excess deaths) Some profits https://www.reuters.com/business/healthcare-pharmaceuticals/drug-companies-face-covid-cliff-2023-sales-set-plummet-2023-02-06/ Western drugmakers are estimated to have brought in about $100 billion in revenue in 2022.